ZURICH (Reuters) – Roche’s Tecentriq immunotherapy combined with other drugs boosted lung cancer patients’ survival versus an older cocktail, the Swiss company said as it seeks an edge on Merck and Bristol-Myers Squibb.
ZURICH (Reuters) – Roche’s Tecentriq immunotherapy combined with other drugs boosted lung cancer patients’ survival versus an older cocktail, the Swiss company said as it seeks an edge on Merck and Bristol-Myers Squibb.